Tagged with Alzheimer's

USA What if ageing itself, not just individual diseases, was the root cause of the most devastating conditions we face? That question has shaped the career of Dr. Joshua Hare, a practising cardiologist and biotech founder who is betting on stem cell therapy to shift how we treat age-related illnesses. Dr.…

Global Alzheimer’s Disease takes a heavy toll; not just on patients and caregivers, but on society as a whole. As populations age, this complex and often-stigmatised condition is becoming harder to ignore. Despite recent breakthroughs, we are still far from having the right tools: better diagnostics, effective treatments, and smarter healthcare…

Denmark Neuroscience is once again at the forefront of medical innovation, and Lundbeck is seizing the moment to redefine its future. In this wide-ranging conversation, President & CEO Charl van Zyl outlines how the company is evolving from a heritage-rich organisation into a focused, performance-driven innovator with a maturing pipeline and…

Global As neuroscience reclaims a place at the top table of pharmaceutical innovation, Bristol Myers Squibb (BMS) is quietly reshaping its presence in the field. Spearheaded by its Neuroscience Thematic Research Center, the company is pursuing a dual mandate: to slow the progression of diseases like Alzheimer’s while also addressing their…

Spain Dr Arcadi Navarro is a leading figure in modern Alzheimer’s research, heading efforts at the Pasqual Maragall Foundation in Barcelona and its university partners. His work spans genomics, bioinformatics, neurotropic viruses, and personalised brain organoids. Under his leadership, the foundation has doubled its research capacity and become a key player…

Singapore Charles Stacey, President and CEO of Cerecin, discusses the company’s strategic direction and partnerships as it advances its Alzheimer’s treatment into Phase 3 trials. He highlights the importance of collaboration with global contract research organizations and large vendors during the clinical development phase. Stacey also shares insights into Cerecin’s approach…

USA As the search for effective Alzheimer’s treatments continues to evolve, Annovis Bio is taking a distinct approach with buntanetap, a novel oral candidate designed to intervene more broadly in disease progression. In this interview, Chief Business Officer Mark White discusses the company’s clinical learnings, operational discipline, and the realities of…

Global As the neuroscience field gains unprecedented momentum, Roche is taking a leading role in redefining how neurodegenerative diseases like Alzheimer’s are understood, diagnosed, and treated. Dr Azad Bonni, Senior Vice President and Global Head of Neuroscience and Rare Diseases at Roche’s Pharma Research and Early Development (pRED), brings a unique…

Global Paola Barbarino, CEO of Alzheimer’s Disease International, shares her insights into the growing global challenge of the disease and the urgent need for action across all income settings. In this interview, she discusses the importance of post-diagnosis support, the burden on caregivers, the impact of stigma, and the role of governments…

China As a result of its ageing demographic, China has seen a sharp rise in Alzheimer’s Disease (AD). The country’s AD patients over 60 already total some ten million and as the population ages, that number is expected to climb. A new report from Selesta looks at the country’s current standards…

Research Andreas Lysandropoulos, Senior Vice President and Global Therapeutic Area Head for Neuroscience at Parexel, shares his insights on the evolving landscape of clinical development for neurological conditions. In this interview, he highlights the importance of localised patient engagement, the role of advocacy in building urgency around diseases like Alzheimer’s, and…

Sweden Even though the development of these treatments takes time, there are many capable people continuing to push the field forward. I believe that lecanemab, BioArctic, and others dedicated to this area will keep innovating, learning, and improving—ultimately leading to better outcomes for patients with Alzheimer’s. Lars Lannfelt, co-founder and board…